Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
VNRX Stock — VolitionRx Limited
VolitionRx Limited (VNRX)
Updated October 16, 2026.
VNRX is a Stock. Total return is -97.7% over the past 19.4 years, 726.3 points behind SPY at 628.6%.
VolitionRx Limited is a multinational epigenetics company that develops blood tests for detecting and monitoring cancers and diseases associated with NETosis, such as sepsis, across the United States, Europe, and Asia. Its product portfolio includes Nu.Q Vet for animal cancer screening, Nu.Q Nets for NETosis-related diseases, Nu.Q Cancer for treatment response prediction and monitoring, and Capture-PCR and Capture-Seq technologies for early cancer detection through circulating tumor DNA analysis. The company does not currently distribute to shareholders.
VNRX performance versus SPY
Price and return data through 2026-10-16.
Total return is -97.7% over the past 19.4 years, 726.3 points behind SPY at 628.6%. Over the past year its total return — price change plus distributions reinvested — is -98.0%. Its deepest 1-year drawdown was 98.0%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -34.5% | — |
| 3M | -84.5% | — |
| 6M | -94.9% | — |
| YTD | -96.5% | — |
| 1Y | -98.0% | — |
| 2Y CAGR | — | -88.90% |
| 3Y CAGR | — | -76.10% |
| 5Y CAGR | — | -69.50% |
| 10Y CAGR | — | -46.60% |
| Since inception (19.4 years) | -97.7% | -17.70% |
VNRX key facts
- Issuer
- VolitionRx Limited
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 05/10/2007
- Distribution frequency
- None
- Last close
- $0.18 (as of 2026-10-16)
- Market cap
- $5,413,926
- Average volume
- 475873.0
- Beta
- 1.166
- Payout ratio
- 0.0%
- Forward P/E
- 20.8333
- EPS
- $-3.66
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: VolitionRx Limited or company page; prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
VNRX risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 98.0%.
Who may consider VNRX — and who may not
It is a weaker fit for investors who need monthly cash flow (VNRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on VNRX
Frequently asked questions
Does VNRX pay monthly?
No. VNRX does not currently distribute.
When does VNRX pay a dividend?
VNRX does not currently distribute.
How has VNRX performed?
Total return is -97.7% over the past 19.4 years, 726.3 points behind SPY at 628.6%. Over the past year its total return — price change plus distributions reinvested — is -98.0%. Its deepest 1-year drawdown was 98.0%.
More securities from VolitionRx Limited.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.